URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

VRNA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.80%

Insider Buying (Last 12 Months): $188,928.00

Insider Selling (Last 12 Months): $9,819,879.28

Verona Pharma Insider Trading History Chart

Verona Pharma Share Price & Price History

^$42.02

▲ +0.8 (1.94%)

As of 12/20/2024 06:51 PM ET

Days: 30 | 90 | 365

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Verona Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2024	David Zaccardelli	CEO	Sell	162,800	$5.01	$815,628.00	14,204,752
12/6/2024	Mark W. Hahn	CFO	Sell	183,728	$5.01	$920,477.28	13,293,736
12/4/2024	David Zaccardelli	CEO	Sell	67,608	$5.00	$338,040.00	15,007,816
12/4/2024	Mark W. Hahn	CFO	Sell	58,184	$5.00	$290,920.00	14,117,512
12/2/2024	David Zaccardelli	CEO	Sell	3,200	$5.00	$16,000.00	15,075,424
12/2/2024	Mark W. Hahn	CFO	Sell	1,600	$5.00	$8,000.00	14,175,696
11/29/2024	David Zaccardelli	CEO	Sell	98,888	$5.01	$495,428.88	15,078,624
11/29/2024	Mark W. Hahn	CFO	Sell	98,704	$5.01	$494,507.04	14,177,296
11/27/2024	David Zaccardelli	CEO	Sell	23,240	$5.00	$116,200.00	15,177,512
11/27/2024	Mark W. Hahn	CFO	Sell	12,936	$5.00	$64,680.00	14,276,000
11/25/2024	Kathleen A. Rickard	Insider	Sell	240,000	$4.90	$1,176,000.00	2,671,480
11/25/2024	Mark W. Hahn	CFO	Sell	1,600	$5.00	$8,000.00	14,289,736
11/11/2024	David Zaccardelli	CEO	Sell	2,400	$5.00	$12,000.00	15,202,352
11/6/2024	David R. Ebsworth	Director	Buy	39,360	$4.80	$188,928.00	920,003
11/4/2024	David Zaccardelli	CEO	Sell	94,144	$4.39	$413,292.16	15,204,752
11/4/2024	Mark W. Hahn	CFO	Sell	80,784	$4.39	$354,641.76	14,293,736
11/1/2024	David Zaccardelli	CEO	Sell	46,888	$4.38	$205,369.44	15,298,896
11/1/2024	Mark W. Hahn	CFO	Sell	48,888	$4.38	$214,129.44	14,374,520
10/25/2024	David Zaccardelli	CEO	Sell	4,800	$4.38	$21,024.00	14,591,736
10/24/2024	Mark W. Hahn	CFO	Sell	141,360	$4.38	$619,156.80	13,672,560
10/23/2024	David Zaccardelli	CEO	Sell	16	$4.38	$70.08	14,736,536
10/21/2024	David Zaccardelli	CEO	Sell	110,456	$4.38	$483,797.28	14,894,464
10/21/2024	Mark W. Hahn	CFO	Sell	116,696	$4.38	$511,128.48	13,973,264
10/18/2024	David Zaccardelli	CEO	Sell	245,784	$4.38	$1,076,533.92	15,004,920
10/18/2024	Mark W. Hahn	CFO	Sell	249,728	$4.38	$1,093,808.64	14,089,960
5/3/2024	Kathleen A. Rickard	Insider	Sell	36,248	$1.96	$71,046.08	2,621,552
11/20/2023	Martin Edwards	Director	Buy	33,736	$1.84	$62,074.24	144,800
11/6/2023	David R. Ebsworth	Director	Buy	160,000	$1.98	$316,800.00	844,643
11/3/2023	Kathleen A. Rickard	Insider	Sell	58,752	$1.92	$112,803.84	2,840,640
8/7/2023	Claire Poll	General Counsel	Sell	1,512	$2.47	$3,734.64	1,907,367
8/7/2023	David Zaccardelli	CEO	Sell	8,616	$2.47	$21,281.52	16,431,800
8/7/2023	Kathleen A. Rickard	Insider	Sell	1,600	$2.47	$3,952.00	2,872,528
8/4/2023	David Zaccardelli	CEO	Sell	150,000	$2.50	$375,000.00	16,440,416
8/3/2023	Claire Poll	General Counsel	Sell	20,608	$2.54	$52,344.32	1,935,231
8/3/2023	Kathleen A. Rickard	Insider	Sell	50,600	$2.55	$129,030.00	2,902,072
8/3/2023	Mark W. Hahn	CFO	Sell	117,272	$2.54	$297,870.88	15,679,864
8/2/2023	David Zaccardelli	CEO	Sell	73,704	$2.59	$190,893.36	16,707,688
8/1/2023	Claire Poll	General Counsel	Sell	18,608	$2.68	$49,869.44	1,968,783
8/1/2023	Kathleen A. Rickard	Insider	Sell	19,736	$2.68	$52,892.48	2,966,400
8/1/2023	Mark W. Hahn	CFO	Sell	105,944	$2.68	$283,929.92	15,870,840
5/15/2023	Orbimed Advisors Llc	Director	Sell	359,713	$20.08	$7,223,037.04	3,777,778
5/11/2023	Orbimed Advisors Llc	Director	Sell	80,000	$22.26	$1,780,800.00	4,180,691
5/3/2023	Kathleen A. Rickard	Insider	Sell	28,752	$2.65	$76,192.80	2,971,136
5/1/2023	Claire Poll	General Counsel	Sell	80,376	$2.58	$207,370.08	1,979,063
5/1/2023	David Zaccardelli	CEO	Sell	455,536	$2.58	$1,175,282.88	16,887,336
5/1/2023	Kathleen A. Rickard	Insider	Sell	77,424	$2.58	$199,753.92	2,999,888
5/1/2023	Mark W. Hahn	CFO	Sell	455,528	$2.58	$1,175,262.24	15,976,784
2/1/2023	Claire Poll	General Counsel	Sell	152,000	$2.59	$393,680.00	774,256
2/1/2023	David Zaccardelli	CEO	Sell	432,928	$2.56	$1,108,295.68	17,342,872
2/1/2023	Kathleen A. Rickard	Insider	Sell	89,960	$2.56	$230,297.60	3,106,064
2/1/2023	Mark W. Hahn	CFO	Sell	413,168	$2.56	$1,057,710.08	16,432,312
12/22/2022	Claire Poll	General Counsel	Sell	240,000	$2.69	$645,600.00	774,256
12/22/2022	Orbimed Advisors Llc	Director	Sell	3,969,496	$21.77	$86,415,927.92	36,255,896
12/20/2022	David Zaccardelli	CEO	Sell	600,000	$2.12	$1,272,000.00	17,775,800
8/9/2022	David Zaccardelli	CEO	Sell	600,000	$1.75	$1,050,000.00	15,263,560
8/2/2022	Kathleen A. Rickard	Insider	Sell	28,752	$0.70	$20,126.40	2,376,040
8/1/2022	David Zaccardelli	CEO	Sell	32,904	$0.70	$23,032.80	15,863,560
8/1/2022	Mark W. Hahn	CFO	Sell	13,168	$0.70	$9,217.60	14,913,496
5/3/2022	David Zaccardelli	CEO	Sell	32,904	$0.50	$16,452.00	16,351,328
5/3/2022	Kathleen A. Rickard	Insider	Sell	28,752	$0.49	$14,088.48	2,461,224
5/3/2022	Mark W. Hahn	CFO	Sell	12,512	$0.50	$6,256.00	15,381,520
4/11/2022	Kathleen A. Rickard	Insider	Sell	59,720	$0.54	$32,248.80	2,546,408
4/8/2022	Kathleen A. Rickard	Insider	Sell	112,800	$0.59	$66,552.00	2,606,128
2/3/2022	David Zaccardelli	CEO	Sell	52,056	$0.73	$38,000.88
2/2/2022	Mark W. Hahn	CFO	Sell	10,416	$0.76	$7,916.16
2/1/2022	Lisa Deschamps	Director	Sell	11,664	$0.78	$9,097.92

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

SEC Filings (Institutional Ownership Changes) for Verona Pharma (NASDAQ:VRNA)

85.88% of Verona Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Verona Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/27/2024	Franklin Resources Inc.	559,728	$16.10M	0.0%	N/A	0.696%
11/25/2024	Sanctuary Advisors LLC	7,597	$0.22M	0.0%	N/A	0.010%
11/16/2024	Geode Capital Management LLC	62,081	$1.79M	0.0%	-5.9%	0.078%
11/15/2024	Frazier Life Sciences Management L.P.	3,383,950	$97.36M	3.9%	+2.1%	4.233%
11/15/2024	Y Intercept Hong Kong Ltd	11,361	$0.33M	0.0%	N/A	0.014%
11/15/2024	Northeast Financial Consultants Inc	8,700	$0.25M	0.0%	N/A	0.011%
11/15/2024	Dorsey Wright & Associates	80,194	$2.31M	0.5%	N/A	0.100%
11/15/2024	Orion Portfolio Solutions LLC	12,051	$0.35M	0.0%	-13.6%	0.015%
11/15/2024	Wellington Management Group LLP	1,878,632	$54.05M	0.0%	+19.6%	2.350%
11/15/2024	Stifel Financial Corp	16,458	$0.47M	0.0%	N/A	0.021%
11/15/2024	Samsara BioCapital LLC	195,225	$5.62M	1.1%	-43.8%	0.244%
11/15/2024	RA Capital Management L.P.	5,009,653	$144.13M	1.7%	-34.4%	6.267%
11/15/2024	Parkman Healthcare Partners LLC	626,452	$18.02M	2.3%	+5.2%	0.784%
11/15/2024	Janus Henderson Group PLC	1,042,795	$30.02M	0.0%	-4.5%	1.304%
11/15/2024	HighVista Strategies LLC	23,739	$0.68M	0.2%	-26.8%	0.030%
11/15/2024	Centiva Capital LP	10,262	$0.30M	0.0%	-37.4%	0.013%
11/14/2024	Bellevue Group AG	1,220,059	$35.10M	0.6%	+7.6%	1.517%
11/14/2024	Caligan Partners LP	1,436,878	$41.34M	13.1%	-22.1%	1.786%
11/14/2024	Maverick Capital Ltd.	4,215,973	$121.29M	2.4%	+36.3%	5.241%
11/14/2024	Eventide Asset Management LLC	2,425,846	$69.79M	1.2%	+359.6%	3.016%
11/14/2024	Verition Fund Management LLC	17,170	$0.49M	0.0%	N/A	0.021%
11/14/2024	Walleye Capital LLC	64,605	$1.86M	0.0%	N/A	0.080%
11/13/2024	Glenmede Trust Co. NA	30,251	$0.87M	0.0%	-13.1%	0.038%
11/13/2024	Townsquare Capital LLC	17,626	$0.51M	0.0%	N/A	0.022%
11/13/2024	BNP Paribas Financial Markets	60,211	$1.73M	0.0%	+176.5%	0.075%
11/13/2024	FMR LLC	716,588	$20.62M	0.0%	-0.4%	0.896%
11/13/2024	The Manufacturers Life Insurance Company	105,159	$3.03M	0.0%	+77.0%	0.132%
11/13/2024	Loomis Sayles & Co. L P	1,111,096	$31.97M	0.0%	N/A	1.390%
11/8/2024	Jennison Associates LLC	1,740,886	$50.09M	0.0%	+54.3%	2.143%
11/7/2024	First Turn Management LLC	572,928	$16.48M	2.6%	N/A	0.705%
11/7/2024	Claro Advisors LLC	7,273	$0.21M	0.0%	N/A	0.009%
11/5/2024	Verus Capital Partners LLC	11,320	$0.33M	0.0%	-34.9%	0.014%
11/5/2024	GSA Capital Partners LLP	29,513	$0.85M	0.1%	N/A	0.036%
11/4/2024	Crossmark Global Holdings Inc.	16,150	$0.47M	0.0%	N/A	0.020%
11/1/2024	Atria Investments Inc	19,054	$0.55M	0.0%	N/A	0.024%
11/1/2024	Cahill Wealth Management LLC	7,745	$0.22M	0.1%	N/A	0.010%
10/30/2024	Rosalind Advisors Inc.	275,000	$7.91M	5.0%	+10.0%	0.344%
10/30/2024	AlphaCentric Advisors LLC	50,000	$1.44M	1.1%	-10.7%	0.063%
10/28/2024	Rice Hall James & Associates LLC	985,076	$28.34M	1.5%	+4.8%	1.213%
10/28/2024	US Bancorp DE	21,955	$0.63M	0.0%	-8.3%	0.027%
10/25/2024	Diversify Wealth Management LLC	21,254	$0.61M	0.1%	N/A	0.027%
10/25/2024	AMI Asset Management Corp	66,346	$1.91M	0.1%	-5.2%	0.083%
10/25/2024	Diversify Advisory Services LLC	5,861	$0.17M	0.0%	N/A	0.007%
10/25/2024	China Universal Asset Management Co. Ltd.	21,041	$0.61M	0.1%	+37.1%	0.026%
10/24/2024	PFG Investments LLC	36,800	$1.06M	0.1%	-17.5%	0.045%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	2,610	$75K	0.0%	+25.4%	0.003%
10/23/2024	Values First Advisors Inc.	17,174	$0.49M	0.3%	N/A	0.021%
10/23/2024	Moody Aldrich Partners LLC	252,752	$7.27M	1.3%	-14.6%	0.316%
10/23/2024	Hennion & Walsh Asset Management Inc.	155,835	$4.48M	0.2%	+14.9%	0.195%
10/17/2024	Claro Advisors LLC	7,273	$0.21M	0.0%	N/A	0.009%
10/7/2024	GAMMA Investing LLC	1,336	$38K	0.0%	+70.6%	0.002%
8/27/2024	Clearbridge Investments LLC	405,819	$5.87M	0.0%	+58.8%	0.508%
8/16/2024	Perceptive Advisors LLC	2,433,725	$35.19M	0.8%	-35.3%	3.011%
8/16/2024	Quarry LP	2,000	$29K	0.0%	-63.6%	0.002%
8/16/2024	Frazier Life Sciences Management L.P.	3,314,349	$47.93M	2.2%	+10.0%	4.101%
8/15/2024	The Manufacturers Life Insurance Company	59,418	$0.86M	0.0%	N/A	0.074%
8/15/2024	Millennium Management LLC	527,640	$7.63M	0.0%	+4.7%	0.653%
8/15/2024	Maverick Capital Ltd.	3,092,807	$44.72M	0.8%	+74.2%	3.827%
8/15/2024	Affinity Asset Advisors LLC	700,000	$10.12M	1.2%	-14.4%	0.866%
8/15/2024	Alerce Investment Management L.P.	213,000	$3.08M	6.0%	N/A	0.264%
8/14/2024	NEA Management Company LLC	5,584,753	$80.76M	6.1%	+9.3%	6.910%
8/14/2024	Marshall Wace LLP	13,500	$0.20M	0.0%	N/A	0.017%
8/14/2024	Hood River Capital Management LLC	1,062,456	$15.36M	0.3%	+7.6%	1.315%
8/13/2024	Sei Investments Co.	66,781	$0.97M	0.0%	-10.1%	0.083%
8/12/2024	Resolute Capital Asset Partners LLC	50,000	$0.72M	0.4%	N/A	0.062%
8/9/2024	Renaissance Technologies LLC	31,044	$0.45M	0.0%	N/A	0.038%
8/8/2024	Federated Hermes Inc.	2,163,600	$31.29M	0.1%	-4.2%	2.677%
8/8/2024	American Century Companies Inc.	878,043	$12.70M	0.0%	+56.6%	1.105%
8/8/2024	Rice Hall James & Associates LLC	939,576	$13.59M	0.8%	+39.0%	1.182%
8/7/2024	PFG Investments LLC	44,600	$0.65M	0.0%	+67.7%	0.055%
8/6/2024	Candriam S.C.A.	772,997	$11.18M	0.1%	N/A	0.956%
8/3/2024	TD Asset Management Inc	121,600	$1.76M	0.0%	N/A	0.150%
8/1/2024	Verus Capital Partners LLC	17,385	$0.25M	0.0%	N/A	0.022%
7/30/2024	Matisse Capital	34,400	$0.50M	0.2%	+77.3%	0.043%
7/29/2024	EMC Capital Management	2,500	$38K	0.0%	N/A	0.003%
7/26/2024	Legato Capital Management LLC	10,670	$0.15M	0.0%	N/A	0.013%
7/25/2024	AMI Asset Management Corp	70,000	$1.01M	0.1%	N/A	0.087%
7/20/2024	Hennion & Walsh Asset Management Inc.	135,629	$1.96M	0.1%	+101.3%	0.171%
7/10/2024	CWM LLC	2,000	$29K	0.0%	N/A	0.003%
5/20/2024	Virtu Financial LLC	23,180	$0.37M	0.0%	N/A	0.029%
5/17/2024	Ikarian Capital LLC	375,310	$6.04M	0.7%	+2.1%	0.464%
5/16/2024	Janus Henderson Group PLC	2,031,994	$32.66M	0.0%	+12.7%	2.514%
5/16/2024	Kennedy Capital Management LLC	123,215	$1.98M	0.0%	-25.6%	0.152%
5/15/2024	Bellevue Group AG	1,139,295	$18.33M	0.3%	+35.6%	1.410%
5/15/2024	Hood River Capital Management LLC	987,756	$15.89M	0.4%	+4.3%	1.222%
5/15/2024	Affinity Asset Advisors LLC	817,833	$13.16M	1.7%	+45.1%	1.035%
5/14/2024	CM Management LLC	35,000	$0.56M	0.5%	N/A	0.043%
5/13/2024	Clearbridge Investments LLC	255,609	$4.11M	0.0%	+2.7%	0.316%
5/8/2024	US Bancorp DE	23,822	$0.38M	0.0%	-43.4%	0.029%
5/7/2024	Sei Investments Co.	74,294	$1.20M	0.0%	+3.7%	0.092%
5/2/2024	Jennison Associates LLC	1,593,833	$25.65M	0.0%	+0.5%	1.972%
5/1/2024	Capstone Investment Advisors LLC	25,616	$0.41M	0.0%	N/A	0.032%
5/1/2024	BNP Paribas Financial Markets	23,412	$0.38M	0.0%	+1,054.4%	0.029%
5/1/2024	Matisse Capital	19,400	$0.31M	0.2%	N/A	0.024%
4/29/2024	China Universal Asset Management Co. Ltd.	20,200	$0.33M	0.0%	+35.8%	0.025%
4/23/2024	Rice Hall James & Associates LLC	675,757	$10.87M	0.6%	+44.1%	0.836%
4/22/2024	PFG Investments LLC	26,600	$0.43M	0.0%	+49.4%	0.033%
4/22/2024	Vivo Capital LLC	3,610,177	$58.09M	4.6%	-15.1%	4.467%
4/17/2024	Hennion & Walsh Asset Management Inc.	67,365	$1.08M	0.1%	+71.4%	0.083%
3/5/2024	Wellington Management Group LLP	3,783,994	$75.23M	0.0%	-15.3%	4.734%

Data available starting January 2016

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $42.02

$40.10

$42.86

50 Day Range

MA: $37.72

$33.11

$42.68

52 Week Range

Now: $42.02

$11.39

$43.73

Volume

733,684 shs

Average Volume

934,459 shs

Market Capitalization

$3.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Who are the company insiders with the largest holdings of Verona Pharma?: Verona Pharma's top insider shareholders include:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Mark W Hahn (CFO)
Kathleen A Rickard (Insider)
Claire Poll (General Counsel)
David R Ebsworth (Director)
Martin Edwards (Director)
Learn More about top insider investors at Verona Pharma.
Who are the major institutional investors of Verona Pharma?: Verona Pharma's top institutional investors include:
RA Capital Management L.P. — 6.27%
Maverick Capital Ltd. — 5.24%
Frazier Life Sciences Management L.P. — 4.23%
Eventide Asset Management LLC — 3.02%
Wellington Management Group LLP — 2.35%
Jennison Associates LLC — 2.14%
Learn More about top institutional investors of Verona Pharma stock.
Which major investors are selling Verona Pharma stock?: Within the previous quarter, VRNA stock was sold by these institutional investors:
RA Capital Management L.P.
Caligan Partners LP
Samsara BioCapital LLC
Janus Henderson Group PLC
Moody Aldrich Partners LLC
HighVista Strategies LLC
PFG Investments LLC
Centiva Capital LP
Within the last year, company insiders that have sold Verona Pharma company stock include:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Mark W Hahn (CFO)
Learn More investors selling Verona Pharma stock.
Which major investors are buying Verona Pharma stock?: In the last quarter, VRNA stock was bought by institutional investors including:
Eventide Asset Management LLC
Maverick Capital Ltd.
Loomis Sayles & Co. L P
Jennison Associates LLC
First Turn Management LLC
Franklin Resources Inc.
Wellington Management Group LLP
Bellevue Group AG
Within the last year, these company insiders have bought Verona Pharma stock:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Learn More investors buying Verona Pharma stock.